ATLANTA, GA – – (Newsfile Corp. – September 22, 2022) – – Holzer & Holzer, LLC informs investors that a class action lawsuit was filed against Humanigen, Inc. (“Humanigen” or the “Company”) (NASDAQ: HGEN). The lawsuit alleges Humanigen made materially false and misleading statements and/or failed to disclose that: (1) its product, lenzilumab, was less effective in treating hospitalized COVID-19 patients than the Company had represented; (2) as a result, the FDA was unlikely to approve an emergency use authorization for lenzilumab and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (3) accordingly, lenzilumab’s clinical and commercial prospects were overstated.
If you bought shares of Humanigen between May 28, 2021 to July 12, 2022, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at firstname.lastname@example.org or Joshua Karr, Esq. at email@example.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at https://holzerlaw.com/case/humanigen/ to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is October 25, 2022.
Lead Plaintiff Deadline Has Passed
October 25, 2022